Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

EC approves Vertex's KALYDECO for treatment of cystic fibrosis

Vertex Pharmaceuticals Incorporated announced today that the European Commission has approved KALYDECOTM (ivacaftor) for people with cystic fibrosis (CF) ages 6 and older who have at least one copy of the G551D mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

28 Jul 2012

Anakinra can dramatically limit amount of brain damage in stroke patients

Scientists led by the President of The University of Manchester have demonstrated a drug which can dramatically limit the amount of brain damage in stroke patients.

From The University of Manchester 27 Jul 2012

Roundup: Ore. Gov. suggests malpractice reform; Mass. Gov. proposes new scrutiny for health care providers; Texas has offered HPV vaccine since 2007

The state can cut health care costs and reduce the number of medical-related lawsuits by requiring earlier notification of injuries as well as pretrial mediation, according to a recommendation Gov. John Kitzhaber issued Wednesday. The product of closed-door talks between representatives of interest groups including the Oregon Medical Association and the Oregon Trial Lawyers Association, Kitzhaber's recommendation now goes to a work group including lawmakers, a trial lawyer and doctor that begins public meetings next week.

27 Jul 2012

FDA approves Horizon Pharma's RAYOS to treat key IL-6 mediated diseases

Horizon Pharma, Inc., announced today that the U.S. Food and Drug Administration (FDA) has approved RAYOS (prednisone) delayed-release tablets (1 mg, 2 mg and 5 mg) to treat a broad range of diseases including rheumatoid arthritis (RA), polymyalgia rheumatica (PMR), psoriatic arthritis (PsA), ankylosing spondylitis (AS), asthma and chronic obstructive pulmonary disease (COPD).

26 Jul 2012

Preliminary findings from Protalex's PRTX-100 Phase 1b study on active rheumatoid arthritis

Protalex, Inc., a clinical stage biopharmaceutical company that is developing a class of drugs designed to treat a wide array of autoimmune and inflammatory diseases today announced preliminary findings from its recently completed Phase 1b randomized, multiple-dose, dose-escalation study.

26 Jul 2012

Regeneron reports total revenues of $304 million for second quarter 2012

Regeneron Pharmaceuticals, Inc. announced financial and operating results for the second quarter of 2012 and provided an update on development programs.

25 Jul 2012

Questcor second quarter net sales increase to $112.5 million

Questcor Pharmaceuticals, Inc. today reported financial results for the second quarter and six months ended June 30, 2012.

24 Jul 2012

Anti-IL-3 monoclonal antibodies to treat early stage Rheumatoid Arthritis in development

SuppreMol GmbH, an autoimmune disease specialist, today announced a licensing agreement with the University Hospital of Regensburg to develop SM401, a humanized anti-IL-3 monoclonal antibody for early diagnosis and treatment of Rheumatoid Arthritis (RA). SuppreMol will advance preclinical development of SM401 for treatment of RA. Simultaneously, the Company will further validate a highly sensitive human IL-3 diagnostic assay for patient stratification.

24 Jul 2012

Researchers discover reason why breast cancer cells become drug resistant

Breast cancer treatments such as Herceptin that target a marker called HER2 have dramatically improved outcomes for women with this type of cancer. But nearly half of these cancers are resistant to Herceptin from the start and almost all of them will eventually become resistant.

21 Jul 2012

Statistical method uses evolutionary information to enhance identification of disease-associated alleles

A book containing misprints may cause annoyance for the reader, but typos in an individual's genetic blueprint (DNA) can mean serious disease or even death. The search for genetic correlates for the wide range of diseases plaguing humankind has inspired a wealth of research falling under the heading of genome-wide association studies (GWAS).

19 Jul 2012

Discrepancies between patients and physicians' views of RA disease activity

Researchers from Austria have determined that patients with rheumatoid arthritis (RA) and their doctors differ on perception of RA disease activity.

18 Jul 2012

Rheumatoid arthritis patients and their doctors differ on perception of disease activity

Researchers from Austria have determined that patients with rheumatoid arthritis (RA) and their doctors differ on perception of RA disease activity. The study now available in Arthritis & Rheumatism, a journal of the American College of Rheumatology (ACR) and published by Wiley, reports that RA patients cite joint pain as the reason for their perception of a change in their disease activity. Rheumatologists, however, stressed joint swelling as the major determinant for their perception of change in RA disease activity.

18 Jul 2012

Anthera announces final set of clinical data from blisibimod Phase 2b study on SLE

Anthera Pharmaceuticals, Inc., a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, today announced the final set of clinical data from the Phase 2b PEARL-SC study in patients with systemic lupus erythematosus.

17 Jul 2012

Rheumatoid arthritis patients take-up cancer screening

Insurance records for rheumatoid arthritis patients in the USA indicate that patients are receiving their recommended cervical, breast, and colon cancer screening tests.

16 Jul 2012

Researchers discover HVEM’s unknown role in fighting off E. coli infections

Despite ongoing public health efforts, E. coli outbreaks continue to infiltrate the food supply, annually causing significant sickness and death throughout the world. But the research community is gaining ground. In a major finding, published today in the scientific journal Nature, researchers from the La Jolla Institute for Allergy & Immunology have discovered a molecule's previously unknown role in fighting off E. coli and other bacterial infections, a discovery that could lead to new ways to protect people from these dangerous microorganisms.

16 Jul 2012

SRI receives NIAID grant to develop HIV vaccine

The Scripps Research Institute has been awarded a grant expected to total more than $77 million from the National Institutes of Health's (NIH) National Institute of Allergy and Infectious Diseases (NIAID).

12 Jul 2012

FDA approves Watson’s ANDA for generic ARTHROTEC

Watson Pharmaceuticals, Inc. today announced that its subsidiary Watson Laboratories, Inc - Florida has received approval from the United States Food and Drug Administration on its Abbreviated New Drug Application (ANDA) for Diclofenac Sodium and Misoprostol Delayed-Release Tablets, the generic equivalent to G.D. Searle's ARTHROTEC.

12 Jul 2012

Rheumatoid arthritis risk reduced by moderate alcohol consumption

Moderate consumption of alcohol is associated with a reduced risk of developing rheumatoid arthritis, suggests a study published on bmj.com today.

11 Jul 2012

Herpes zoster vaccine recommendations questioned in patients on biologics

Administration of the live attenuated herpes zoster vaccine is not associated with an increased risk for shingles shortly after vaccination in patients receiving biologic treatments for immune-mediated diseases, researchers report in JAMA.

10 Jul 2012

RA patients do not receive fewer cancer screening tests than general population: Study

New research reveals that rheumatoid arthritis (RA) patients do not receive fewer cancer screening tests than the general population. Results of the study, funded in part by grants from the National Institutes of Health (NIH) and published in Arthritis & Rheumatism, a journal of the American College of Rheumatology (ACR), found that RA and non-RA patients receive routine screening for breast, cervical, and colon cancer at similar rates.

10 Jul 2012

Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

EC approves Vertex's KALYDECO for treatment of cystic fibrosis

Anakinra can dramatically limit amount of brain damage in stroke patients

Roundup: Ore. Gov. suggests malpractice reform; Mass. Gov. proposes new scrutiny for health care providers; Texas has offered HPV vaccine since 2007

FDA approves Horizon Pharma's RAYOS to treat key IL-6 mediated diseases

Preliminary findings from Protalex's PRTX-100 Phase 1b study on active rheumatoid arthritis

Regeneron reports total revenues of $304 million for second quarter 2012

Questcor second quarter net sales increase to $112.5 million

Anti-IL-3 monoclonal antibodies to treat early stage Rheumatoid Arthritis in development

Researchers discover reason why breast cancer cells become drug resistant

Statistical method uses evolutionary information to enhance identification of disease-associated alleles

Discrepancies between patients and physicians' views of RA disease activity

Rheumatoid arthritis patients and their doctors differ on perception of disease activity

Anthera announces final set of clinical data from blisibimod Phase 2b study on SLE

Rheumatoid arthritis patients take-up cancer screening

Researchers discover HVEM’s unknown role in fighting off E. coli infections

SRI receives NIAID grant to develop HIV vaccine

FDA approves Watson’s ANDA for generic ARTHROTEC

Rheumatoid arthritis risk reduced by moderate alcohol consumption

Herpes zoster vaccine recommendations questioned in patients on biologics

RA patients do not receive fewer cancer screening tests than general population: Study

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Newsletters you may be interested in